|
Oct 9
|
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
|
|
Oct 7
|
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
|
|
Oct 4
|
Moleculin to Present at Two Upcoming Investor Conferences
|
|
Aug 26
|
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
|
|
Mar 20
|
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
|
|
Mar 19
|
Moleculin Announces Reverse Stock Split
|
|
Dec 21
|
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
|
|
Dec 20
|
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
|
|
Dec 11
|
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
|
|
Oct 24
|
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
|
|
Aug 7
|
Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling
|
|
Jul 13
|
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
|
Apr 24
|
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
|